Primary Central Nervous System Lymphoma in Adults

A multidisciplinary team works together to provide you with personalized care for primary central nervous system lymphoma. This rare, fast-growing type of non-Hodgkin lymphoma can start in the brain, eyes, spinal cord, or meninges, which are the layers of tissue that cover and protect the brain and spinal cord. We use the newest genetic tests to determine what therapies are best for you. Your treatment plan may include chemotherapy, targeted drugs, and radiation therapy. You may also be eligible to participate in , which offer access to promising new medications.

Clinical Trials and Research Studies

Phase 1/2

An Open-Label Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination with REGN2810 in Subjects with Newly-Diagnosed Glioblastoma (GBM)

Phase 1/2

AN OPEN-LABEL MULTICENTER PHASE l/1B TRIAL EVALUATING THE SAFETY ANDPHARMACOKINETICS OF ESCALATING DOSES OF BTCT4465A AS A SINGLE AGENT ANDCOMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORYB-CELL NON-HODGKIN S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA

Phase 2

CDA Chi BMS A phase II trial of nivolumab ipilimumab and short course radiotherapy in newly diagnosed glioblastoma patients with unmethylated MGMT promoter BMS-936558 and BMS-734016

Phase 2

APEC1621C: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex